Premium
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia
Author(s) -
Marley Stephen B.,
Davidson R. John,
Goldman John M.,
Gordon Myrtle Y.
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03237.x
Subject(s) - alpha interferon , clonogenic assay , tretinoin , progenitor cell , cancer research , cytarabine , interferon , alpha (finance) , retinoic acid , medicine , pharmacology , immunology , stem cell , myeloid leukemia , cell , biology , cell culture , biochemistry , genetics , construct validity , nursing , patient satisfaction
Summary. Combination of STI571, a tyrosine kinase inhibitor, with other drugs may be beneficial in the treatment of chronic myeloid leukaemia (CML). We measured the effects of STI571, AG490, farnesyltransferase inhibitor (FTI), interferon alpha (IFN‐α), cytosine arabinoside (Ara‐C) and all‐ trans retinoic acid (ATRA), singly and in combination, on clonogenic leukaemic cell proliferation. STI571, IFN‐α and ATRA each reduced proliferation by 50–60%; AG490, FTI and Ara‐C had less effect. Comparing the observed and expected (i.e. additive) effects of drug combinations showed STI571 + FTI, STI571 + AG490 and IFN‐α+ ATRA were additive; STI571 + IFN‐α, IFN‐α+ Ara‐C and STI571 + AG490 + FTI were less than additive. Thus, STI571 + FTI, STI571 + AG490 and IFN‐α+ ATRA may be better combination therapies for CML than STI571 + IFN‐α, IFN‐α+ Ara‐C or STI571 + AG490 + FTI.